9 month tox data clears the way for a run at $10++ and either a EU partnership or a buy-out
Their drug discovery platform is also going to be a value driver when they start to put drugs into P1 development.
These antibiotics are all going to get fast tracked under the new FDA trial guidelines.
their is no doubt that a bigger player is going to buy TSRX for a big fat premo.
The recent results of a 9 month toxicity study showing that tedizolid does not produce optic or peripheral neuropathies at concentrations of up to 6-fold its therapeutic exposure (maximum dose tested) suggests that tedizolid may be suitable for the treatment of complicated bacteremia and other diseases requiring long term dosing. By contrast, linezolid at 1x its therapeutic exposure shows neuropathies within 3 months.